GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTPW) » Definitions » Cash And Cash Equivalents

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Cash And Cash Equivalents : $2.90 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals Cash And Cash Equivalents?

60 Degrees Pharmaceuticals's quarterly cash and cash equivalents declined from Sep. 2023 ($2.22 Mil) to Dec. 2023 ($2.14 Mil) but then increased from Dec. 2023 ($2.14 Mil) to Mar. 2024 ($2.90 Mil).

60 Degrees Pharmaceuticals's annual cash and cash equivalents increased from Dec. 2021 ($0.12 Mil) to Dec. 2022 ($0.27 Mil) and increased from Dec. 2022 ($0.27 Mil) to Dec. 2023 ($2.14 Mil).


60 Degrees Pharmaceuticals Cash And Cash Equivalents Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals Cash And Cash Equivalents Chart

60 Degrees Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
0.19 0.12 0.27 2.14

60 Degrees Pharmaceuticals Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.02 2.22 2.14 2.90

60 Degrees Pharmaceuticals Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


60 Degrees Pharmaceuticals  (NAS:SXTPW) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


60 Degrees Pharmaceuticals Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases through Arakoda and Celgosivir.

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Headlines